Akorn’s sterile plant receives US FDA warning letter

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/	LiudmylaSupynska)
(Image: Getty/ LiudmylaSupynska)

Related tags: Sterile Injectables, Fda, Form 483, Warning letter, illinois

Akorn received a warning letter from the FDA on January 4, relating to the inspection of its manufacturing facility in Decatur, Illinois, in April and May 2018.

The US Food and Drug Administration’s letter to Akorn cited violations of current good manufacturing practice (cGMP) regulations, including procedures related to monitoring the plants environment and personnel. Additionally, the agency noted foreign fibers and contaminants on gloves that were supposed to be sterile.

The warning letter came after Akorn’s response to the FDA’s Form 483 issued in November was deemed inadequate by the agency.

Akorn’s Decatur plant manufactures sterile filled liquid injectables, sterile lyophilized injectables, ophthalmic bottle sterile filled liquid, prescription, over the counter, and controlled drug substances.

Neither the warning letter nor the previous Form 483 were the first instances of FDA action regarding Akorn’s facility.

In 2016, the FDA filed a Form 483 to the same plant after observations of quality control​. The agency found traces of foreign matter in some of the plant’s drug batches and the company was unable to find the root cause of the matter. Later in 2016, the FDA re-inspected​ the plant and issued a positive observation.

Moreover, Akorn’s CEO resigned​ in December 2018 and the company has not yet announced a replacement for the former CEO, Raj Rai.

Following this most recent letter, Akorn’s shares dropped by 8.9%.

The company expects to continue production at the plant.

Related news

Related products

show more

Shifting the Biomanufacturing Paradigm

Shifting the Biomanufacturing Paradigm

BioContinuum™ Platform - MilliporeSigma | 01-Jul-2020 | Technical / White Paper

Adoption of next generation processing and technologies can enable improvements in productivity by streamlining workflows, reducing the manufacturing plant...

Bio4C™ ProcessPad Software Datasheet

Bio4C™ ProcessPad Software Datasheet

BioContinuum™ Platform - MilliporeSigma | 01-Jul-2020 | Data Sheet

Biopharmaceutical processes are complex and highly variable in nature. This can result in inconsistent and sometimes unpredictable process outcomes. To...

Related suppliers

Follow us


View more